Home > Insider Trading > Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc. (LXRX)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
31 - 40
Next >>

These Biotech Stocks Move in Opposing Directions Today and Hedge Funds Say You Should Bet on One of Them

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) are up by more than 20% in early trading, following positive Phase 2 reports on HTX-011, an anesthetic and anti-inflammatory drug designed to lower pain...

Keep Reading →

September 23rd, 2015 - Hedge Funds News

Lexicon Pharmaceuticals, Inc. (LXRX) Flies On Cancer Drug Study Results; Hedge Funds Saw This Coming

Shares of Lexicon Pharmaceuticals, Inc.

Keep Reading →

August 3rd, 2015 - Hedge Funds News

Nektar Therapeutics (NKTR): Insiders Aren't Crazy About It But Hedge Funds Love It

Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.

Keep Reading →

September 17th, 2013 - News

Acorda Therapeutics Inc (ACOR): Insiders Aren't Crazy About It But Hedge Funds Love It

To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.

Keep Reading →

September 11th, 2013 - News

PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?

In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.

Keep Reading →

September 3rd, 2013 - News

Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?

In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.

Keep Reading →

August 30th, 2013 - News

Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)

If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.

Keep Reading →

August 30th, 2013 - News

Lexicon Pharmaceuticals, Inc. (LXRX), Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Why Clinical Trials Fail

Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.

Keep Reading →

August 30th, 2013 - News

What Hedge Funds Think About VIVUS, Inc. (VVUS)

In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market. A couple of the most underrated are hedge fund and insider trading movement.

Keep Reading →

August 22nd, 2013 - News

Lexicon Pharmaceuticals, Inc. (LXRX), Merck & Co., Inc. (MRK): The Worst-Performing Biotech Stocks of the Last Decade

Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at $500 million or more written on them.

Keep Reading →

July 24th, 2013 - News